The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Dear Reader, the StratCom Team takes this opportunity to wish you the very best holiday season and a New Year of health and peace on earth. Thank you for your continued support. Best wishes, Shara Rosen AviaraDx has discovered that a two-gene ratio of HOXB13/IL17BR (H/I) is a strong independent prognostic marker in estrogen-receptor-positive (ER+), node-negative breast cancer patients that may or may not have received anti-hormonal treatment. CombiMatrix Molecular Diagnostics launched a test that discriminates malignant melanoma from benign moles that is based on CombiMatrix Corporation's CustomArray platform. Corbett Life Science introduced its Rotor-Gene rotary-based thermocycler. The centrifugal design, reports Corbett, results in much greater thermal and optical uniformity and is the cornerstone of Corbett's conceptually novel thermocycler instruments. DiagnoCure's PCA3 gene test, marketed by Gen-Probe, was awarded the CE mark. The companies believe that the marker is a much more precise indicator of prostate cancer than current diagnostics. Fluidigm Corporation launched its BioMark dynamic arrays, a new platform for gene expression analysis that runs gold standard TaqMan assays on nanofluidic chips. The BioMark system is expected to replace 384-microwell plate systems. Kimball Genetics launched its Warfarin Sensitivity DNA Test for research/investigational purposes. The test determines the presence of specific variations in the CYP2C9 and VKORC1 genes that confer sensitivity to warfarin. Kimball Genetics expects to offer the Warfarin Sensitivity DNA Test for routine clinical use early in 2007. SIRS-Lab GmbH has identified specific gene expression signatures for sepsis. During the next 18 months, SIRS-Lab will advance these new classifiers into a CE-approved quick test based on established biochip and qPCR platforms.
Molecular Biology - October 2006
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
Send mail to stratcom@total.net with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: December 04, 2006 |